English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Chronic kidney disease (CKD) and mineral disorders are one of the most common reasons of cats. Alterations in mineral metabolism occur in early stage of CKD and increasing the severity in advanced stages. In Turkey, although some clinical studies on CKD in cats are available, no data concerning the clinical significance of pretreatment Ca-P solubility product is present. The purpose of the current study was to determine of Ca-P solubility product and its association with the life quality of cats with CKD. Staging system for classifying cats with chronic kidney disease was based on IRIS guideline. The following groups were occurred based on serum creatinine (SCr) and urine specific gravity 5.0 mg/dl. Solubility product (calcium x phosphorus) was also defined. Although calcium levels were within reference ranges in groups, Ca-P product were above 72 mg 2 /dl 2 in stage 3 and 4 cats. In conclusion, determination of pretreatment Ca-P solubility product in cats with different stages of CKD could be useful to modify and manage the life quality of cats with CKD.

Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease